Announced Thu, 9 Jul · 17:20 IST
Filing of dematerialization compliance certificate for Q1 FY27
Compliance View source PDF
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.9%1-day move
₹961.55
prior close
₹965.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.0-1.4-0.9-0.7+1.9+1.1+0.8+0.4-1.7-0.1————
Up moveDown movePending
AI summary
Natco Pharma submitted a compliance certificate from its registrar (Venture Capital and Corporate Investments) under SEBI Regulation 74(5) for the quarter ended June 30, 2026. The certificate confirms that physical shares received for dematerialization were mutilated and cancelled after verification, and that the records of NSDL and CDSL depositories were updated as the registered owner within 15 days. This is a routine quarterly regulatory filing.
Likely market impact
Routine compliance filing - no financial impact on shareholders or stock price.